Compare AMPL & XNCR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPL | XNCR |
|---|---|---|
| Founded | 2012 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.2B | 2.0B |
| IPO Year | 2021 | 2013 |
| Metric | AMPL | XNCR |
|---|---|---|
| Price | $17.41 | $37.50 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 11 | 14 |
| Target Price | $21.27 | ★ $42.50 |
| AVG Volume (30 Days) | ★ 1.9M | 1.6M |
| Earning Date | 11-04-2026 | 11-04-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.84 | ★ 65.36 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $343,214,000.00 | $125,576,000.00 |
| Revenue This Year | $21.64 | $57.39 |
| Revenue Next Year | $16.99 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 14.68 | 13.65 |
| 52 Week Low | $5.51 | $10.38 |
| 52 Week High | $18.85 | $40.60 |
| Indicator | AMPL | XNCR |
|---|---|---|
| Relative Strength Index (RSI) | 60.76 | 69.59 |
| Support Level | $15.62 | $22.80 |
| Resistance Level | $17.84 | N/A |
| Average True Range (ATR) | 0.91 | 2.07 |
| MACD | -0.08 | 0.74 |
| Stochastic Oscillator | 54.61 | 75.23 |
Amplitude Inc is a Software company that provides a Digital Analytics Platform that helps companies analyze their customer behavior within digital products. The Company delivers its application over the Internet as a subscription service using a software-as-a-service (SaaS) model and also it offers customer support related to initial implementation setup, ongoing support services, and application training. The company generates revenue through selling subscriptions to the platform. The company derives a majority of its revenue from the United States, and also has its presence in Internationally.
Xencor Inc is a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab and XmAb657. The group earns its revenue from collaboration agreements and licensing agreements and operates as a single reportable segment focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases who have unmet medical needs.